Skip to main content
. 2019 Jun 6;10:1304. doi: 10.3389/fimmu.2019.01304

Figure 6.

Figure 6

(A) IL-6 concentrations in the three groups, with a significant difference between the control group vs. the 30 mg/Kg.d group; (B) IL-8 concentrations in the three groups, with a significant difference between the control group vs. the 7.5 mg/Kg.d and 30 mg/Kg.d groups; (C) TNF-α concentrations in the three groups, with a significant difference between the control group vs. the 7.5 mg/Kg.d and 30 mg/Kg.d groups; (D) IL-1β concentration in the three groups, with a significant difference between the control group vs. the 7.5 mg/Kg.d and 30 mg/Kg.d groups; (E) Immunohistochemistry results indicated that Kirenol can inhibit the level sof IL-6, IL-8, and TNF-α in the synovium. (F) Western blotting indicated that Kirenol can inhibit the levels of IL-6, IL-8, and TNF-α in the synovium. (G) IL-6, IL-8, and TNF-α levels differed significantly between the 30 mg/kg group and the other experimental groups. *p < 0.05, **p < 0.01, ***p < 0.01 as assessed by the Kruskal-Wallis test and the Mann-Whitney U-test.